

Cellomics: Trusted Biotechnology Empowerment




Founded in 2019, Cellomics International Ltd. (Cellomics) is committed to providing a full range of precision diagnostic products and services for cancer screening and detection. The company has a life science and precision medicine research center in Hong Kong and a GMP production base and a medical laboratory in the Greater Bay Area. Cellomics is a national high-tech enterprise integrating precision medical liquid biopsy technology research and development, product transformation, production, and sales and testing services.

We are committed to promoting cancer detection services and promoting our platform products from China to other countries. Cellomics aspires to be a global leader in liquid biopsy and precision medicine, and we work with international partners to help doctors and patients to create a healthier world!

StartUpBeat

研究新聞
城大成功研發精準癌症血液檢測技術

城大新技術 5分鐘驗癌九成準



黃博士 (左)、梁博士 (右) 及其他生物醫學系團隊成員於研發出精準癌症早期篩檢及遠程監測的突破性技術。
香港城市大學 (城大) 的生物醫學研究團隊，成功研發出精準癌症早期篩檢和遠程監測的突破性技術，病人只需透過4毫升血液檢查，五分鐘後即可分離出癌細胞，準確率達九成，讓病人盡快得知患癌風險；同時可監



Health Screening Service - Circulating Rare Cells Detection

Cancer has always been known as the number one killer of diseases, threatening our health.

Early detection and intervention of cancer are critical to prolong survival.

Circulating Rare Cell (CRC) is found in the early stages of the development of tumorigenesis, a small number of abnormal cells may enter the human blood circulation system. CRC Monitoring is necessary for **people with high risk factors for cancer** (senior members, family history of cancer, patients with hepatitis and/or cirrhosis, long-term smoking, alcohol consumption, long-term working stress, low immunity, etc.).

CRC檢測適用癌症類型 Target Cancer Type





Image of CRC



CRC - Clinical Applications

> Early screening

At an ultra-early stage of tumorigenesis, CRC can be detected in the blood

Seize the best period for tumor treatment

> Prognosis

The monitoring of CRCs and gene mutation provide additional information for prognosis and treatment planning

> Relapse alert

Re-detection or the detection of CRC number increment, and mutations in relapse/metastasis-related genes are the precursors of tumor recurrence/metastasis



> Efficacy and drug resistance assessment

Monitoring the dynamic change of CRC number and resistance gene mutations are effective to determine drug effectiveness and prediction of drug resistance in patient


> Tumor dynamic monitoring

Dynamically monitors the number of CRCs and EMT subtypes

> Precision treatment

Develop individualized treatment strategies and select targeted therapies or immunotherapy options

Cellomics: 可信賴的生物科技賦能



晶准生物科技有限公司(晶准)成立於2019年, 致力於為癌症篩查和檢測提供全方位的精準診斷產品及服務。公司在香港設有生命科學和精準醫學研究中心以及在大灣區建立GMP生產基地和醫學檢驗所, 是集精準醫療液體活檢技術研發、產品轉化、生產、銷售、檢測服務為一體的國家級高新技術企業。

我們致力推動癌症檢測服務, 以及將我們的平台產品由中國推至其他國家。晶准立志成為液體活檢和精準醫學的全球領導者, 並與國際合作夥伴合作, 幫助醫生和患者創造一個更健康的世界!



鄧博士 (左)、張博士 (右) 及其他生物醫學系團隊成員於研發出精準癌症血液檢測技術後合影。

香港城市大學 (城大) 的生物醫學研究團隊, 成功研發出精準癌症早期篩查和疾病監測的突破性技術, 病人只需透過4毫升血液檢查, 五分鐘後即可分離出癌細胞, 準確率逾九成, 讓病人盡快得知患病風險; 同時可監



健康監測-血液循環異常細胞分析服務


CRC檢測適用癌症類型 Target Cancer Type¹

癌症一直被譽為疾病中的頭號殺手，嚴重威脅人民健康。

癌症的早預防、早發現、早治療意義重大。

血液循環異常細胞 (CRC) 是在腫瘤發生發展的早期，少量異常細胞可能進入人體血液循環系統。CRC監測對於有**癌症高危因素的人群** (高齡、直系親屬患癌、肝炎肝硬化患者、長期吸煙、飲酒、長期工作壓力大、免疫力低下等) 非常有必要。

CRC圖示



CRC具有豐富的臨床應用

> 早篩早診

腫瘤發生的超早期, 血液中即可檢測CRC
抓住腫瘤治療的最佳時期

> 輔助分期及預後

根據CRC數目及基因突發, 判斷預後及治療方案

> 復發預警

CRC重新檢出或數目增多, 復發/轉移相關基因突變是腫瘤復發/轉移的先兆



> 療效及耐藥性評估

動態CRC數目及耐藥性基因突變, 判斷藥物有效性以及患者預測耐藥

> 腫瘤動態監測

動態監控CRC數目及EMT亞型

> 即時精准治療

制定個體化治療策略, 選擇標靶治療或免疫治療方案